WIPO – 检索国际和国家专利汇编

1.WO/2022/099187SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF

WO - 12.05.2022

国际分类 A61P 11/00 申请号 PCT/US2021/058593 申请人 PRESIDENT AND FELLOWS OF HARVARD COLLEGE 发明人 ABRAHAM, Jonathan

The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen- binding proteins, pharmaceutical compositions, and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.

2.20210353620Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor

US - 18.11.2021

国际分类 A61K 31/496 申请号 17320069 申请人 The University of Vermont and State Agricultural College 发明人 Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

3.20230357366Antigen Binding Molecules Targeting SARS-CoV-2

US - 09.11.2023

国际分类 C07K 16/10 申请号 18313306 申请人 Generate Biomedicines, Inc. 发明人 Francesco Borriello

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

4.WO/2022/015573SARS-COV-2 ANTIGEN-BINDING PROTEINS AND USES THEREOF

WO - 20.01.2022

国际分类 A61K 39/42 申请号 PCT/US2021/040900 申请人 PRESIDENT AND FELLOWS OF HARVARD COLLEGE 发明人 ABRAHAM, Jonathan

The present invention provides severe acute respiratory syndrome coronavirus (SARS-CoV), e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-binding proteins and methods of use thereof to passively immunize and treat subjects having or at risk of having a SARS-CoV, e.g., SARS-CoV-2, infection.

5.WO/2021/206638VACCINE AND/OR ANTIBODY FOR VIRAL INFECTION

WO - 14.10.2021

国际分类 C07K 14/165 申请号 PCT/SG2021/050197 申请人 INTRA-IMMUSG PRIVATE LIMITED 发明人 ZENG, Qi

The present invention relates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N-protein and/or an immunogenic fragment thereof and uses thereof. The invention also includes a nucleic acid molecule encoding the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof; and uses thereof. The SARS-CoV-2 N protein and/or immunogenic fragment thereof may be produced by recombinant DNA technology or may be chemically synthesised. In particular, the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof and/or nucleic acid molecule encoding the SARS-CoV-2 N-protein and immunogenic may be for use as a vaccine. The invention further includes an antibody capable of binding to the SARS-CoV-2 N-protein or antigen-binding fragment thereof and uses thereof.

6.WO/2006/086561NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS

WO - 17.08.2006

国际分类 A61K 39/00 申请号 PCT/US2006/004599 申请人 NEW YORK BLOOD CENTER 发明人 JIANG, Shibo

The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.

7.WO/2024/026553NOVEL ANTIGENIC EPITOPE AGAINST SARS-COV-2 AND USES THEREOF

WO - 08.02.2024

国际分类 C07K 14/165 申请号 PCT/CA2022/051182 申请人 CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL 发明人 FINZI, Andrés

The present application discloses antigenic peptides that are recognized by neutralizing anti-SARS-CoV-2 antibodies. Neutralizing antibodies targeting these antigenic peptides are effective against several SARS-CoV-2 variants. Conjugates, vesicles, pharmaceutical compositions and vaccines comprising the antigenic peptides, as well as antibodies recognizing these antigenic peptides, are also disclosed. The antigenic peptides and encoding nucleic acids, conjugates, antibodies or antigen-binding fragments thereof, vesicles, pharmaceutical compositions or vaccines described herein may be used for the prevention and/or treatment of coronavirus infection and/or associated diseases and symptoms, such as SARS-CoV-2 infection and/or COVID-19.

8.WO/2023/159316FORMULATION OF ANTI-SARS-COV-2 NEUTRALIZING ANTIBODIES AND USES THEREOF

WO - 31.08.2023

国际分类 A61K 39/42 申请号 PCT/CA2023/050235 申请人 IMMUNE BIOSOLUTIONS INC. 发明人 FUGÈRE, Alexandre

The present application relates to a composition comprising a combination of anti-SARS- CoV-2 antibodies or antigen-binding fragments thereof, or of nucleic acids encoding the anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. Methods and uses of the compositions for the prevention and/or treatment of betacoronavirus infections and related diseases such as COVID-19, are also described. The compositions may be administered in the respiratory tract, e.g., in nebulized or aerosolized form, to subjects infected with or at risk of being infected with a coronavirus such as SARS-CoV-2.

9.WO/2021/228092NOVEL MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF

WO - 18.11.2021

国际分类 C07K 16/10 申请号 PCT/CN2021/093083 申请人 CHANG GUNG MEMORIAL HOSPITAL, LINKOU 发明人 HUANG, Kuan-Ying

Provided are novel monoclonal antibodies or the antigen-binding fragments thereof, which bind to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or angiotensin-converting enzyme 2 (ACE2). Also provided are a pharmaceutical composition and a kit for detecting the presence of SARS-CoV-2 in a sample comprising the novel monoclonal antibody or the antigen-binding fragments thereof. Also disclosed herein are methods for detection or prevention and/or treatment of SARS-CoV-2 or a disease mediated by a disease mediated by ACE2.

10.WO/2021/257607TREATMENT FOR HUMAN CORONAVIRUS INFECTION

WO - 23.12.2021

国际分类 A61K 39/395 申请号 PCT/US2021/037486 申请人 THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND 发明人 BIX, Gregory Jaye

Treating a human coronavirus (hCoV) infection includes administering an effective amount of an inhibitor of an α5- or αv-containing integrin to a subject in need thereof. The integrin inhibitor can be ATN-161. The hCoV can be SARS-CoV or SARS-CoV-2.

1 / 107

转到检索输入栏	`CTRL` + `SHIFT` +
转到结果（选定结果）	`CTRL` + `SHIFT` +
转到详细信息（选定标签）	`CTRL` + `SHIFT` +
转到下一页	`CTRL` +
转到上一页	`CTRL` +

转到下一个结果/图像	/
转到上一个结果/图像	/
向上滚动	`Page Up`
向下滚动	`Page Down`
滚动至顶部	`CTRL` + `Home`
滚动至底部	`CTRL` + `End`

正在处理

进入国家阶段

规范文件

设置

反馈

查看申请

保存查询

查询树

优化选项

完整查询

并排视图快捷键

分析

转到下一个标签
转到上一个标签